N/A N=30 Marginal Bone and Soft Tissue Alterations After Use of OsseoSpeed EV Profile Implants
Alveolar Process Atrophy
Primary: Pink Esthetic Score (PES) at Temporary Crown Delivery. — 1; 1; 1; 1 score on a scale — p=0.0007
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=163 Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
Chronic Myeloid Leukemia
Primary: Percentage of Patients in Treatment Free Remission (TFR) Within 48 Weeks — 57.9 Percentage of participants
Phase 4 N=40 Comparing Blood Loss and Visualization After the Preoperative Use of Topical 0.05% Oxymetazoline Versus 1:1000 Epinephrine Prior to Endoscopic Sinus Surgery
Endoscopic Sinus Surgery · Nasal Polyps
Primary: Surgical Field Visualization During Sinus Surgery as Indicated by Score on Boezaart Grading Scale — 3; 2.55 score on a scale
Phase 1 N=62 Delayed Versus Early Enoxaparin Prophylaxis After Traumatic Brain Injury (TBI)
Venous Thromboembolism · Traumatic Brain Injury
Primary: Percentage of Participants With Worsening TBI Hemorrhage — 5.9; 3.6 percentage of participants
Phase 2 N=36 Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy
Castration-Resistant Prostate Carcinoma · Metastatic Malignant Neoplasm in the Bone · Metastatic Malignant Neoplasm in the Soft Tissues
Primary: Percentage of Participants With a >= 50% Decline in Prostate-specific Antigen (PSA) Value — 73.5 percentage of subjects
Phase 3 N=41 Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL
B-Cell Non Hodgkin Lymphoma
Primary: Phase 2: Percentage of Participants Who Achieved Complete Metabolic Response (CMR) — 22.0 Percentage of participants
Phase 2 N=24 Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in Narcolepsy
Narcolepsy · Excessive Sleepiness
Primary: Standard Deviation of Lateral Position (SDLP) at 2 Hours Post-dose (Approximately at Tmax) — 20.46; 19.08 centimeter (cm) — p=0.0022
Phase 2 N=15 Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors
Bladder Cancer
Primary: Evaluate the Efficacy for Treatment of Low/Intermediate- Risk Bladder Tumors, Assessing for the Clinical Response of the Marker Lesion — 13 Participants
Phase 4 N=100 Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults
Major Depressive Disorder · Dysthymic Disorder · Depressive Disorder, NOS
Primary: Hamilton Rating Scale for Depression (HRSD) — 13.3 score on a scale
Phase 2 N=159 Temozolomide 12 Cycles Versus 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma.
Glioblastoma
Primary: Progression Free Survival at 6 Month — 61.3; 55.7 percentage of patients
Phase 4 N=498 A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study
Diabetes Mellitus, Type 2
Primary: Percentage of Time Spent in Glycaemic Target Range 70-180 mg/dL (3.9-10.0 mmol/L) Both Inclusive, Using Flash Glucose Monitoring (FGM) — 72.11; 70.68 Percentage of Time…
N/A N=13 Clinical Trial Testing the BioSerenity Pulse Oximeter (EOXY) Efficacy, Performance and Safety in Healthy Volunteer
Healthy
Primary: Percentage SPO2 Accuracy Root-Mean Square (ARMS) at Forehead Position — 3.91; 3.08; 3.36; 2.85 percentage of ARMS (accuracy)
Phase 2 N=31 Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor
Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Myelodysplastic Syndrome
Primary: Transplant-related Mortality (TRM) — 13 Kaplan-Meier estimates (%)
Phase 2 N=92 Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer
Breast Cancer
Primary: Number of Patients Who Developed Grade 2-3 Acute Radiation Dermatitis Within 60 Days Post-RT — 8 Participants
Phase 3 N=68 Efficacy of the Combination of Isosorbide Dinitrate Spray and Chitosan in Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Biopsies — 2.46; 2.64; 2.56; 2.07 UI/dL